Abstract
The effects of phosphate binder therapies (calcium carbonate, calcium acetate, or aluminum hydroxide) on copper status were assessed in 88 adult patients with end-stage renal disease on hemodialysis. Subjects were divided into two groups based on binder therapy compliance as specified by medical criteria established by the Health Care Financing Administration. Binder compliant subjects (n = 62), aged 59.7+/-12.2 yr, maintained serum phosphorus concentrations of 3.5-6.0 mg/dL. Noncompliant subjects (n = 26), aged 54.2+/-13.8 yr, had serum phosphorus concentrations > 6.0 mg/dL. Mean plasma and red blood cell (RBC) copper, serum ceruloplasmin, and erythrocyte superoxide dismutase activity did not differ between binder compliant and noncompliant subjects. Mean RBC copper, plasma copper, and serum ceruloplasmin concentrations of hemodialysis subjects were within normal limits, despite copper intakes of less than two-thirds of the lower limit of the Estimated Safe and Adequate Daily Dietary Intakes for copper. The phosphate binder therapies (calcium carbonate, calcium acetate, and/or aluminum hydroxide) had no effect on the copper status of patients with end-stage renal disease on hemodialysis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
